Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02467335 · ClinicalTrials.gov registry record · Phase 1
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02467335 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 52 participants.
The verdict
NCT02467335, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.
Interventions
- DRUG BMS-663068
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-01-29 |
| Est. Completion | 2015-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02467335
The ClinicalTrials.gov registry entry for NCT02467335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-663068 is the first listed.
NCT02467335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02467335 about?
NCT02467335 is a clinical study titled "Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects". A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.
What is the current status of trial NCT02467335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2015-01-29. Estimated completion is 2015-10-03.
What interventions are being tested in trial NCT02467335?
The interventions under investigation include: BMS-663068 (DRUG).
Who is sponsoring clinical trial NCT02467335?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.